Quidel Gets FDA Clearance for Multiplex Strep Assay | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said today that it has received de novo clearance from the US Food and Drug Administration to market its Lyra Direct Strep multiplex real-time PCR assay.

The new test detects and differentiates between pyogenic Group A and pyogenic C or G streptococcal throat infections.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.